Trial reportClinical oral implants research2025
Surgical Treatment of Peri-Implantitis Combined With Keratinized Mucosa Augmentation: Results of a Dual-Center 3-Year RCT.
Trial report in Clinical oral implants research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo evaluate the medium-term efficacy of using a xenogeneic collagen matrix to augment the width of the peri-implant keratinized mucosa (PIKM) as an adjunct to the surgical treatment of peri-implantitis. MATERIAL AND
methodsIn this 36-month parallel-arm randomized controlled clinical trial, patients with peri-implantitis were randomly assigned to a combined protocol of resective peri-implantitis surgery and a PIKM augmentation procedure, either with an autologous free gingival graft (FGG) or a collagen matrix (CM). Primary outcomes were the increase in the width of PIKM and probing pocket depth (PPD) reduction at 36 months. As secondary outcomes, radiographic and patient-reported outcomes were assessed.
resultsForty-one patients (20 in the CM group and 21 in the FGG group) completed the three-year follow-up. PIKM increased in both groups, but the increase was significantly higher in the APF (apically positioned flap) + FGG group compared to the APF + CM group [2.0 (95% CI: 1.3, 2.7) mm in the FGG group compared to 1.0 (95% CI: 0.5, 1.5) mm in the CM group; p = 0.048]. PPDs were reduced by 1.5 mm (95% CI: 1.1, 1.9) and 1.4 mm (95% CI: 0.6, 2.2), respectively. Disease resolution (maximum one site with bleeding on probing, no suppuration, no further bone loss > 0.5 mm, and PD ≤ 5 mm) was 47.6% in the FGG group and 35.0% in the CM group.
conclusionTested surgical modalities resulted in similar improvements in the clinical parameters. Both FGG and CM increased the PIKM, but PIKM was greater at the 36-month examination in the FGG group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.